Reported 1 day ago
A recent bullish thesis on Abbott Laboratories from the r/ValueInvesting subreddit highlights the company's strong quarter results and growth potential in its devices and nutrition segments. Currently priced at $120.51, ABT shows attractive returns with a DCF target price range indicating potential upside. While not deeply undervalued, ABT is viewed as a stable long-term investment with solid cash flow generation and resilience, ideal for investors seeking steady compounding with limited downside risk.
Source: YAHOO